Tag Archives: CH

Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector

Oct 1 (Reuters) – Positive clinical trial results for Merck & Co’s (MRK.N) experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker’s stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.

Merck shares jumped as much as 12.3% and hit their highest level since February 2020 after data showed the company’s pill molnupiravir could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19. Experts hailed the news as potentially a huge advance in the fight against COVID-19.

At the same time, shares of vaccine makers such as Moderna Inc (MRNA.O), Pfizer Inc (PFE.N) and partner BioNTech SE were hit, with some analysts saying the promise of an oral drug that can be taken at home could change the public perception of risks associated with COVID-19.

“We see modest perceived headwind to vaccine stocks such as MRNA (Moderna) if the market thinks people will be less afraid of COVID-19 and less inclined to get vaccines, if there is a simple pill that can treat COVID-19,” Jefferies analyst Michael Yee said in a client note.

Moderna shares tumbled 13% in midday trading, while Pfizer, which is developing a COVID-19 pill of its own, fell 1.3%. U.S. shares of BioNTech dropped 11%.

For Moderna investors, the Merck news presented an opportunity to lock in gains after an already stunning run. Shares of Moderna, which were added to the S&P 500 in mid July, remain up some 220% in 2021 despite Friday’s declines. BioNTech’s shares were also still up about 200% for the year, even with Friday’s fall.

The Merck news is a “great reason for folks to be taking profits off the table” in Moderna and BioNTech shares, said Sahak Manuelian, head of equity trading at Wedbush Securities. “These moves can get exacerbated to the downside given the momentum they have had to the upside.”

FILE PHOTO: Vials of coronavirus disease (COVID-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny

Read More

Shares of other companies with COVID-19 vaccines also fell, with AstraZeneca (AZN.L) down 2% and Novavax (NVAX.O) falling 16%.

Companies with other COVID-19 therapies that are administered intravenously or through injection also traded lower, with Regeneron Pharmaceuticals In (REGN.O) down nearly 5% and Gilead Sciences Inc (GILD.O) off about 2%.

Healthcare (.SPXHC) was the only one of the 11 S&P 500 sectors in negative territory in mid-day trading, falling 0.5%.

“We see molnupiravir, with its oral format as a clear game changer that is likely to meaningfully impact not just the treatment paradigm for COVID-19 but also has potential utility in the prevention setting,” Piper Sandler analyst Christopher Raymond said in a research note.

Merck is conducting a late-stage trial to see if its antiviral pill can prevent COVID-19 infection, in addition to the study that showed it can significantly cut hospitalization and death in those already infected.

Merck, whose shares were last up about 9%, leads the race in developing the first oral antiviral medication for COVID-19. Rivals such as Pfizer and Swiss drugmaker Roche Holding AG (ROG.S) with partner Atea Pharmaceuticals Inc (AVIR.O) are running late-stage trials of their pills. Atea shares were up 19%. read more

Merck, which discontinued its own COVID-19 vaccineprogram, had seen its shares fall about 4% for the year through Thursday, before they moved into positive territory for 2021 on Friday.

“Merck has kind of been dead in the water to investors for the past couple of quarters,” said Kevin Gade, portfolio manager with Bahl & Gaynor, which owns Merck shares. “This shows their R&D engine is not dead and they were first … in what could be a multi-billion dollar opportunity.”

Reporting by Lewis Krauskopf in New York and Manojna Maddipatla in Bengaluru; Editing by Ira Iosebashvili and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Swiss look set to accept same-sex marriage in referendum

Posters are pictured before a vote on same sex marriage in Geneva, Switzerland, September 23, 2021. Poster reads : “Love without privilege, yes to marriage for all”. REUTERS/Denis Balibouse

ZURICH, Sept 26 (Reuters) – Swiss voters on Sunday looked set to back a proposal to open civil marriage and the right to adopt children to same-sex couples, according to early indications published by Swiss broadcaster SRG.

Projections showed 64% of voters had voted in favour of same-sex marriage in a nationwide referendum conducted under Switzerland’s system of direct democracy. A final result is expected later in the day.

“We are very happy and relieved,” said Antonia Hauswirth of the national committee “Marriage for All”, adding supporters would celebrate in Switzerland’s capital Bern on Sunday.

Amnesty International said in a statement that opening civil marriage to same-sex couples was a “milestone for equality”.

However, Monika Rueegger of Switzerland’s right-wing Swiss People’s Party (SVP) and member of the referendum committee “No to Marriage for All” said she was disappointed.

“This was not about love and feelings, it was about children’s welfare. Children and fathers are the losers here,” she told Reuters.

The amended law will make it possible for same-sex couples to get married, and to adopt children unrelated to them. Married lesbian couples would also be allowed to have children through sperm donation, currently legal only for married heterosexual couples.

It will also make it easier for foreign spouses of a Swiss individual to get citizenship. read more

In a separate referendum, 66% of Swiss voters looked set to reject a proposal to introduce a capital gains tax.

Reporting by Silke Koltrowitz; Editing by Angus MacSwan, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

China Evergrande bondholders in limbo over debt crisis

  • No sign of Evergrande paying dollar bond interest
  • Company has 30-day grace period before the bonds default
  • PBOC injects cash into banking system; Evergrande shares fall

SINGAPORE, Sept 24 (Reuters) – China Evergrande slipped toward a kind of limbo on Friday as time ticked away on an interest payment deadline which global markets are watching for signs of default, leaving investors on tenterhooks over the embattled property giant’s fate.

The company owes $305 billion, has run short of cash and markets are worried a collapse could pose systemic risks to China’s financial system and reverberate around the world.

China’s central bank again injected cash into the banking system on Friday, seen as a signal of support for markets. But authorities have been silent on Evergrande’s predicament and China’s state media has offered no clues on a rescue plan.

Evergrande (3333.HK) appointed financial advisers and warned of default last week, and world markets fell heavily on Monday amid fears of contagion, though they have since stabilised.

At its offices, furious small investors have protested to try and retrieve life savings sunk into its properties and wealth-management products.

Evergrande has promised to prioritise such investors and resolved one coupon payment on a domestic bond this week, giving markets a glimmer of hope. But it has said nothing about an $83.5 million offshore interest payment that was due on Thursday or a $47.5 million payment due next week.

It enters a 30-day grace period if it fails to pay Thursday’s dues and would be in default if that window passed without settling the debt. Bondholders are starting to think it might be a month or so before things become clearer.

As Friday trade got underway in Hong Kong, there had been no announcements about a payment. A company spokesperson did not respond to requests for comment.

“Current market pricing estimates that investors in Evergrande’s dollar bonds are likely to recover very little,” said Jennifer James, a portfolio manager and lead emerging markets analyst at Janus Henderson Investors.

“The likeliest outcome is that the company will engage with creditors to come up with a restructuring agreement,” she said.

“How China handles Evergrande, and others, could be consequential. If mismanaged, then the loss of confidence could have contagion effects to other financial markets.”

PLAY FOR TIME

Global markets have begun a recovery following a sharp selloff, trading on the basis that Evergrande’s troubles can be contained.

Only some $20 billion of Evergrande’s debts are owed offshore. Yet the risks at home are considerable because a collapse could crash the property sector which comprises a quarter of China’s economy and is an important store of wealth.

“Housing sales and investments could inevitably slow further – this would knock nearly 1 percentage point off GDP growth,” analysts at Societe Generale said in a note.

“The longer policymakers wait before acting, the higher the hard-landing risk.”

Yet there have so far been few signs of official intervention. The People’s Bank of China’s 270 billion yuan ($42 billion) cash injection this week is the largest weekly sum since January and has helped put a floor under stocks.

Bloomberg Law also reported that regulators had asked Evergrande to avoid a near-term default, citing unnamed people familiar with the matter.

However the Wall Street Journal said, citing unnamed officials, that authorities had asked local governments to prepare for Evergrande’s downfall.

“Given the deliberate pace of Chinese policy making, the authorities may well choose to play for time,” said Wei-Liang Chang, a macro strategist at DBS Bank in Singapore.

He said they could extend liquidity assistance through the grace period on Evergrande’s coupon payments, given it had no dollar bond maturities looming until March 2022.

Evergrande’s shares handed back some Thursday gains on Friday and fell 3%, while stock of its electric-vehicle unit (0708.HK) dropped 18% to a four-year low. Its dollar bonds with imminent payments due , last traded around 30 cents on the dollar.

($1 = 6.4589 Chinese yuan renminbi)

Reporting by Tom Westbrook. Additional reporting by Clare Jim in Hong Kong and Andrew Galbraith in Shanghai; Editing by Stephen Coates

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

BioNTech to seek approval soon for vaccine for 5-11 year olds-Spiegel

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration

FRANKFURT, Sept 10 (Reuters) – BioNTech (22UAy.DE) is set to request approval across the globe to use its COVID-19 vaccine in children as young as five over the next few weeks and preparations for a launch are on track, the biotech firm’s two top executives told Der Spiegel.

“Already over the next few weeks we will file the results of our trial in five to 11 year olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told the news weekly.

The confident statements underscore the lead that BioNTech, which collaborates with Pfizer (PFE.N), holds in the race to win broad approval to vaccinate children below the age of 12 in Western countries.

BioNTech has said it expected to file its regulatory dossier on the five to 11 year olds in September. It has also laid out plans to seek approval in children aged 6 months to 2 years later this year.

Tuereci also told Spiegel that final production steps were being adjusted to bottle a lower-dose pediatric version of its established Comirnaty vaccine. It is currently approved for adults and youngsters at least 12 years of age.

The raw trial data was now being prepared for a regulatory filing and “things are looking good, everything is going according to plan”, Chief Executive Ugur Sahin told Der Spiegel.

Runner-up Moderna (MRNA.O) said on Thursday a trial testing its shot in children between six and 11 years was now fully enrolled and that it was working on the best dosage in another study involving infants as young as six months.

China has been ahead in lowering the age limit of its immunisation campaign. The country’s health authorities in June approved emergency use of Sinovac’s (SVA.O) vaccine in children as young as three years. read more

Chile, which has relied heavily on Sinovac’s shot, this month approved use of the vaccine in children over 6 years of age. read more

Israel’s health ministry said in July that children as young as five can get the Pfizer-BioNTech shot if they suffer from conditions that make them particularly vulnerable to COVID-19.

Reporting by Ludwig Burger, editing by Emma Thomasson, Douglas Busvine, Elaine Hardcastle

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Injured Swiss cows get helicopter ride from Alpine pastures

KLAUSENPASS, Switzerland, Aug 27 (Reuters) – Cows injured during their summer sojourn in the high Swiss Alpine meadows got a jump on their healthier herdmates on Friday when they got helicopter rides down the mountain.

A cow is transported by a helicopter after its summer sojourn in the high Swiss Alpine meadows near the Klausenpass, Switzerland August 27, 2021. REUTERS/Arnd Wiegmann

Read More

A dozen beasts got the lift to land near the Klausenpass mountain pass, around 1,950 metres (6,400 feet) above sea level.

The rest of the 1,000-strong herd was due to head down this weekend to the Urnerboden area in the central canton of Uri in the annual bovine parade.

Reporting by Arnd Wiegmann, writing by Michael Shields, Editing by Rosalba O’Brien

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Dollar, yen on back foot as risk sentiment revives; Musk buoys bitcoin

  • Risk appetite returns as strong earnings lift Wall Street
  • Euro firmer against dollar ahead of ECB policy decision
  • Musk hints Tesla will accept bitcoin as payment again

TOKYO, July 22 (Reuters) – The safe-harbour U.S. dollar and yen were on the back foot on Thursday, after pulling back from multi-month highs amid a recovery in risk appetite as strong earnings lifted Wall Street stocks.

Cryptocurrencies held gains after Tesla Inc (TSLA.O) CEO Elon Musk said the company would “most likely” resume accepting bitcoin for payment. read more

The dollar index , which measures the currency against six major peers, stood at 92.770 after pulling back from a 3 1/2-month high of 93.194 touched on Wednesday.

The yen traded at 129.950 per euro , from an almost four-month top of 128.610 earlier this week, and at 81.07 to Australia’s dollar , from a 5 1/2-month peak of 79.85.

“Strong earnings have swept away Delta concerns in the U.S.,” weighing on haven currencies, National Australia Bank analyst Tapas Strickland wrote in a note to clients.

“The consensus is that (the Delta strain) does not pose an immediate risk to the recovery,” delaying reopening by three months at the most as countries ramp up vaccination drives in response, he said.

Sterling traded at $1.3717, recovering from a 5 1/2-month trough of $1.35725 reached on Tuesday, despite rising Delta variant cases in Britain and confusion about the lifting of restrictions in England.

The Aussie changed hands at $0.7350, from an eight-month low of $0.72895 the previous day, even as coronavirus cases spiked despite half the Australian population being under lockdown. read more

The euro stood at $1.1789, rising off Wednesday’s 3-1/2-month low of $1.1752 ahead of a closely watched European Central Bank policy decision later in the global day.

Policymakers will implement for the first time changes to their strategy and are all but certain to promise an even longer period of stimulus to make good on its commitment to boost inflation. read more

Analysts generally see ECB dovishness weakening the euro over the medium-term.

“On balance, the ECB’s new inflation target suggests monetary policy will remain ultra‑accommodative for an even longer period of time,” which will act as a headwind for the euro, Commonwealth Bank of Australia strategists Kim Mundy and Carol Kong wrote in a research note.

“Indeed, we expect the ECB will be one of the last central banks under our coverage to tighten policy.”

In cryptocurrencies, bitcoin held Wednesday’s 7.9% jump – the biggest since mid-June – to trade just north of$32,000.

Rival ether traded slightly below $2,000 following a 12% surge.

========================================================

Currency bid prices at 0525 GMT

All spots

Tokyo spots

Europe spots

Volatilities

Tokyo Forex market info from BOJ

Reporting by Kevin Buckland; Editing by Sam Holmes

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Cardinal among 10 indicted by Vatican for financial crimes

  • Pope approved move against cardinal, who says he is innocent
  • Former head of Vatican Financial Intelligence denies charges
  • Becciu most senior Vatican official charged with financial crime
  • Trial to start July 27

VATICAN CITY, July 3 (Reuters) – A prominent Italian cardinal was among 10 people sent to trial in the Vatican on Saturday charged with financial crimes including embezzlement, money laundering, fraud, extortion and abuse of office.

Cardinal Angelo Becciu, formerly a senior official in the Vatican administration, as well as two top officials at the Vatican’s Financial Intelligence Unit will go on trial on July 27 over a multi-million euro scandal involving the Vatican’s purchase of a building in one of London’s smartest districts.

The trial will inevitably bring a swirl of media interest to the tiny city-state surrounded by Rome, and appears to underscore Pope Francis’ determination to cure the rot in Vatican finances, even if it involves messy public hearings.

Becciu, 73, whom the pope fired from his senior clerical post last year for alleged nepotism, and who has always maintained his innocence during a two-year investigation, becomes the most senior Vatican official to be charged with financial crimes.

The pope personally gave the required approval last week for Becciu to be indicted, according to a 487-page indictment request seen by Reuters. The Vatican announced the indictments in a two-page statement.

The charges against Becciu include embezzlement and abuse of office. An Italian woman who worked for him was charged with embezzlement and the cardinal’s former secretary, a priest, was accused of extortion.

Becciu said in a statement that he was a victim of a “machination” and reaffirmed his “absolute innocence”.

Two Italian brokers, Gianluigi Torzi and Raffaele Mincione, were charged with embezzlement, fraud and money laundering. Torzi, for whom Italian magistrates issued an arrest warrant in April, was also charged with extortion.

There was no immediate response to attempts to reach their lawyers, but both men have consistently denied wrongdoing.

Four companies associated with individual defendants, two in Switzerland, one in the United States and one in Slovenia, were also indicted, according to the document.

POLICE RAID

The investigation into the purchase of the building became public on Oct. 1, 2019, when Vatican police raided the offices of the Secretariat of State, the administrative heart of the Catholic Church, and those of the Vatican’s Financial Information Authority (AIF).

The then-president of the AIF, Rene Bruelhart, a 48-year-old Swiss, and AIF’s former Italian director, Tommaso Di Ruzza, 46, were charged with abuse of office for allegedly failing to adequately protect the Vatican’s interests and giving Torzi what the indictment request called an “undue advantage”.

Di Ruzza was also accused of embezzlement related to alleged inappropriate use of his official credit card, and of divulging confidential information.

Bruelhart said in a text message that he had “always carried out my functions and duties with correctness” and that “the truth about my innocence will emerge.”

Di Ruzza did not immediately respond to a voicemail requesting comment.

In 2014, the Secretariat of State invested more than 200 million euros, much of it from contributions from the faithful, in a fund run by Mincione, securing about 45% of a commercial and residential building at 60 Sloane Avenue in London’s South Kensington district.

The indictment request said Mincione had tried to deceive the Vatican, which in 2018 tried to end the relationship.

It turned to Torzi for help in buying up the rest of the building, but later accused him of extortion.

‘ENORMOUS LOSSES’

At the time, Becciu was in the last year of his post as deputy secretary of state for general affairs, a powerful administrative position that handles hundreds of millions of euros.

All told, the Secretariat of State sank more than 350 million euros into the investment, according to Vatican media, and suffered what Cardinal George Pell, the former Vatican treasurer, told Reuters last year were “enormous losses”.

Torzi was arrested in the Vatican in June 2020, and spent a week in custody.

According to the indictment request, Becciu is charged with five counts of embezzlement, two of abuse of office, and one count of inducing a witness to perjury. About 75 pages of the document are dedicated to Becciu.

It says Becciu tried to “heavily deflect” the inquiry into Vatican investments, including the London building, and tried to discredit the investigating magistrates via the Italian media.

Becciu continued to have influence over money transfers at the Secretariat even after he left the post, the document said.

The main charges against Becciu involve the alleged funnelling of money and contracts to companies or charitable organisations controlled by his brothers on their native island of Sardinia.

Another Sardinian, Cecilia Maronga, 40, who worked for Becciu, was charged with embezzlement. Her cellphone was not connected.

The indictment request said she had received about 575,000 euros from the Secretariat of State in 2018-2019.

She has said on Italian television that the money, sent to her company in Slovenia, was to ransom kidnapped missionaries in Africa. But the indictment request said much of it was used for “personal benefit”, including the purchase of luxury goods.

Reporting by Philip Pullella; Editing by Kevin Liffey

Our Standards: The Thomson Reuters Trust Principles.

Read original article here